LI-COR aligns with Johns Hopkins for prostate imaging agent
LI-COR Biosciences has entered into a licensing agreement with Johns Hopkins University in Baltimore for compounds and imaging methods targeting prostate-specific membrane antigen (PSMA) developed in the laboratory of Martin G. Pomper, MD, a neuroradiologist at Johns Hopkins.
As an enzyme with an extracellular active site, PSMA represents an excellent target for imaging and therapy directed toward solid tumor neovasculature in addition to prostate cancer itself.
LI-COR plans to manufacture a low molecular weight PSMA-based molecular imaging agent, YC-27, labeled with its proprietary infrared dyes as molecular imaging probes for research purposes. The low molecular weight PSMA-based near-infrared imaging agent IRDye 800CW YC-27 was first published by Chen et al in Biochemical and Biophysical Research Communications in 2009, according to the Lincoln, Neb.-based company.
As an enzyme with an extracellular active site, PSMA represents an excellent target for imaging and therapy directed toward solid tumor neovasculature in addition to prostate cancer itself.
LI-COR plans to manufacture a low molecular weight PSMA-based molecular imaging agent, YC-27, labeled with its proprietary infrared dyes as molecular imaging probes for research purposes. The low molecular weight PSMA-based near-infrared imaging agent IRDye 800CW YC-27 was first published by Chen et al in Biochemical and Biophysical Research Communications in 2009, according to the Lincoln, Neb.-based company.